16
Participants
Start Date
August 31, 2005
Primary Completion Date
January 31, 2008
Study Completion Date
January 31, 2008
Merck L-830982
The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
Placebo
Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
University of Pittsburgh, Pittsburgh
Merck Sharp & Dohme LLC
INDUSTRY
University of Pittsburgh
OTHER